HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

cytochrome P-450 omega-hydroxylase

forms 20-hydroxyeicosatetraenoic acid (20-HETE); do not confuse with arachidonic acid omega-3 hydroxylase which forms 18-HETE
Also Known As:
CYP omega-hydroxylase; arachidonic acid omega-hydroxylase
Networked: 6 relevant articles (1 outcomes, 3 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Gross, Garrett J: 3 articles (03/2009 - 12/2004)
2. Nithipatikom, Kasem: 3 articles (03/2009 - 12/2004)
3. Falck, John R: 2 articles (02/2006 - 12/2004)
4. Campbell, William B: 2 articles (02/2006 - 12/2004)
5. Lombard, J H: 2 articles (12/2001 - 05/2000)
6. Falck, J R: 2 articles (12/2001 - 05/2000)
7. Ao, Ying: 1 article (10/2008)
8. Cheng, Hao: 1 article (10/2008)
9. Peng, Rengxiu: 1 article (10/2008)
10. Li, Ying: 1 article (10/2008)

Related Diseases

1. Ischemia
10/31/2008 - "Taken together, these data suggest that CYP omega-hydroxylase inhibition exerts significant anti-apoptosis effects, at least in part, by activation of ERK1/2 in ischemia/reperfusion heart."
03/01/2009 - "Inhibition of the CYP omega-hydroxylase pathway, stimulation of the CYP-epoxygenase pathway and administration of exogenous epoxyeicosatrienoic acids resulted in cardioprotection in animal models of ischemia; contractile function was improved in mouse hearts subjected to global ischemia/reperfusion, and infarct size was reduced in canine and rat hearts. "
12/01/2004 - "Inhibition of 20-hydroxyeicosatrienoic acid (20-HETE), by pretreatment with pharmacological inhibitors of cytochrome P450 (CYP) omega-hydroxylase, has been shown to reduce infarct size in canines when administered prior to ischemia. "
02/01/2006 - "In this study, we demonstrated that a specific CYP omega-hydroxylase inhibitor, N-methylsulfonyl-12,12-dibromododec-11-enamide (DDMS), markedly reduced 20-HETE production during ischemia-reperfusion and reduced myocardial infarct size compared with control [19.5 +/- 1.0% (control), 9.6 +/- 1.5% (0.40 mg/kg DDMS), 4.0 +/- 2.0% (0.81 mg/kg DDMS), P < 0.01]. "
10/31/2008 - "To further assess the role of mitogen-activated protein kinases (MAPKs) in the CYP omega-hydroxylase inhibitor-induced anti-apoptotic effect, rats also received PD98059 (1 mg/kg), SB203580 (1 mg/kg) or SP600125 (6 mg/kg) 15 min prior to ischemia, with subsets of rats also receiving HET0016 10 min prior to ischemia. "
2. Hypertension (High Blood Pressure)
3. Myocardial Ischemia (Ischemic Heart Diseases)
4. Reperfusion Injury
5. Myocardial Infarction

Related Drugs and Biologics

1. Acids
2. DDMS
3. 20-hydroxy-5,8,11,14-eicosatetraenoic acid
4. Mitogen-Activated Protein Kinases
5. Miconazole (Monistat)
6. Cytochrome P-450 Enzyme System (Cytochrome P450)
7. anthra(1,9-cd)pyrazol-6(2H)-one
8. N- methylsulfonyl- 6- (2- propargyloxyphenyl)hexanamide
9. PD 98059
10. SB 203580